Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Journey Medical Corporation Announces Closing of Initial Public Offering

Nov 16, 2021

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

Nov 15, 2021

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

Nov 12, 2021

Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

Nov 12, 2021

Journey Medical Corporation Prices $35.2 Million Initial Public Offering

Nov 12, 2021

Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency

Nov 10, 2021

Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock

Nov 09, 2021

Journey Medical Corporation Announces Launch of its Initial Public Offering

Nov 08, 2021

Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results

Nov 04, 2021

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

Nov 04, 2021
RSS
  • Prev
    • 1...
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • ...52
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2023 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap